Abcuro

Breakthrough Therapies for Autoimmune Diseases and Cancer

Newton, United States · Founded 2015 · $407.3M raised

Employees
51–200
Founded
2015
Business Model
B2B
Website
abcuro.com
Total Funding
$407.3M
Last Round
$200.0M Series CFeb 2025
Rounds
5

About

Abcuro is a clinical-stage biotechnology company developing first-in-class immunotherapies targeting KLRG1 (Killer cell Lectin-like Receptor G1) for rare autoimmune diseases and cancers. Its lead candidate ulviprubart (ABC008) is in Phase 2/3 pivotal trials for Inclusion Body Myositis (IBM) and Phase 1 trials for T-Cell Large Granular Lymphocytic Leukemia (T-LGLL). The company has raised over $200M in Series C financing led by New Enterprise Associates with participation from Sanofi Ventures, RA Capital, and Bain Capital Life Sciences.

Summary

Abcuro is a Biotech company based in Newton, United States, founded in 2015. It has raised $407.3M in total across 5 rounds, most recently a $200.0M Series C round in Feb 2025. Investors include Sanofi Ventures, Bain Capital Life Sciences and Redmile Group.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

Series CSeries CFeb 2025
$200.0M

Sign up to see all 5 rounds

Seed through Series C — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Abcuro on Indexed.vc
<a href="https://indexed.vc/companies/abcuro"><img src="https://indexed.vc/api/badge/company/abcuro" alt="Abcuro on Indexed.vc" width="260" height="76" /></a>